Redifferentiation Therapy-Returning to Our Roots in a Post-Kinase Inhibitor World.

Cabanillas, Maria E; Busaidy, Naifa L; Sherman, Steven I

Cabanillas, Maria E; Busaidy, Naifa L; Sherman, Steven I.

Afiliação

Cabanillas ME; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, Texas.
Busaidy NL; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, Texas.
Sherman SI; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, Texas.

Clin Cancer Res ; 28(19): 4164-4166, 2022 10 03.

Article em En | MEDLINE | ID: mdl-35895318

ABSTRACT

ABSTRACT

Radioactive iodine (RAI) treatment is an effective treatment for differentiated thyroid cancer (DTC); however, many patients are refractory. Using targeted drugs to reinduce RAI sensitivity ("redifferentiation therapy") has long been sought after as the holy grail in endocrine oncology. See related article by Weber et al., p. 4194.

Assuntos

Adenocarcinoma; Neoplasias da Glândula Tireoide; Adenocarcinoma/tratamento farmacológico; Humanos; Radioisótopos do Iodo/uso terapêutico; Estudos Prospectivos; Inibidores de Proteínas Quinases/uso terapêutico; Neoplasias da Glândula Tireoide/tratamento farmacológico

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Glândula Tireoide / Adenocarcinoma Tipo de estudo: Observational_studies Limite: Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google